|
**Overview**: **Lipid Profile Extended Profile****Introduction**: The Lipid Profile Extended Profile is a diagnostic tool designed for extended lipid screening using serum samples. Associated with conditions like hyperlipidemia and atherosclerosis, these disorders present with chest pain, fatigue, and severe complications if untreated, particularly in individuals with cardiovascular concerns. Per the 2023 Biochemistry guidelines, the test employs biochemistry with spectrophotometry technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for lipid screening in clinical settings. This diagnostic falls under lipid screening and targets individuals with suspected cardiovascular disease, addressing the challenge of accurate lipid assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Lipid Ext Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1970s by metabolic labs, this test advanced extended lipid diagnostics.**Purpose**: The test screens for 11 parameters including total cholesterol to guide lipid assessment, assess cardiovascular risk, and inform treatment and prevention strategies.**Test Parameters**: 1. Total Cholesterol, 2. HDL, 3. LDL, 4. Triglycerides, 5. VLDL, 6. Non-HDL Cholesterol, 7. LDL/HDL Ratio, 8. Total Cholesterol/HDL Ratio, 9. Apolipoprotein A1, 10. Apolipoprotein B, 11. Lipoprotein (a).**Pretest Condition**: Fasting 10-12 hours required; patients should report chest pain, fatigue, or recent cardiovascular symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on chest pain, fatigue, prior cardiovascular reactions, or family history of heart disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hyperlipidemia including heart attack, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent food intake can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hyperlipidemia, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in cardiology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: ECG or stress test for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry Guidelines 2023, Journal of Cardiology 2024, Chemistry 2025. |
